These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37324454)

  • 41. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Web-Based Prediction Models for Overall Survival and Cancer-Specific Survival of Patients With Primary Urachal Carcinoma: A Study Based on SEER Database.
    Ding L; Xia B; Zhang Y; Liu Z; Wang J
    Front Public Health; 2022; 10():870920. PubMed ID: 35719613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.
    Collazo-Lorduy A; Castillo-Martin M; Wang L; Patel V; Iyer G; Jordan E; Al-Ahmadie H; Leonard I; Oh WK; Zhu J; McBride RB; Cordon-Cardo C; Solit DB; Sfakianos JP; Galsky MD
    Eur Urol; 2016 Nov; 70(5):771-775. PubMed ID: 27178450
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
    Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J
    Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
    Wang JY; Xiu J; Baca Y; Arai H; Battaglin F; Kawanishi N; Soni S; Zhang W; Millstein J; Shields AF; Grothey A; Weinberg BA; Marshall JL; Lou E; Khushman M; Sohal DPS; Hall MJ; Oberley M; Spetzler D; Shen L; Korn WM; Lenz HJ
    Ann Oncol; 2021 Jul; 32(7):906-916. PubMed ID: 33798656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma.
    Ma YT; Yang HL; Yan L; Hua F; Wang DG; Xu GY; Li Y; Xue YJ; Qin YJ; Sha D; Ning H; Zhao MQ; Yao ZG
    Pathol Oncol Res; 2022; 28():1610638. PubMed ID: 36338826
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications.
    Guo L; Tang X; Wong SW; Guo A; Lin Y; Kwok HF
    Front Pharmacol; 2022; 13():1022129. PubMed ID: 36582540
    [No Abstract]   [Full Text] [Related]  

  • 55. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma.
    Cornejo KM; Cosar EF; Paner GP; Yang P; Tomaszewicz K; Meng X; Mehta V; Sirintrapun SJ; Barkan GA; Hutchinson L
    Int J Surg Pathol; 2020 Feb; 28(1):51-59. PubMed ID: 31496327
    [No Abstract]   [Full Text] [Related]  

  • 59. Results and challenges of immune checkpoint inhibitors in colorectal cancer.
    Emambux S; Tachon G; Junca A; Tougeron D
    Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Urachal cancer - current concepts of a rare cancer (German version)].
    Reis H; Szarvas T
    Pathologe; 2018 Dec; 39(Suppl 2):291-300. PubMed ID: 30470871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.